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I enjoyed reading the interesting article by Wu et al. (1),
in which the authors demonstrated a significant relationship
between matrix metalloproteinase (MMP)-9, a profibrotic and
proinflammatory molecule, and recurrence of persistent atrial
fibrillation (AF) after catheter ablation. The authors also reported
that left atrial (LA) diameter and a history of AF were inde-
pendent predictors of AF recurrence after ablation therapy.
In recent years, the term fibrotic atriocardiomyopathy
(FACM) has been proposed to define the atrial remodeling
process resulting in atrial myocyte abnormalities and causing
fibrosis in patients with lone AF (2). Previous studies have
confirmed that the majority of patients with AF without
apparent structural heart disease (referred to as ‘lone’ AF)
exhibit a chronically fibrotic bi-atrial substrate (3). Electro-
anatomical mapping and cardiac magnetic resonance ima-
ging with delayed enhancement (DE-MRI) are clinical tools
that are potentially useful for diagnosing FACM (4,5). Atrial
fibrosis is a critical pathophysiological abnormality of the
atrial substrate; is associated with electrical, contractile, and
structural remodeling of atrial tissue; and is involved in both
the initiation and the maintenance of AF (6,7). The MMP
family regulates the degradation of atrial collagen and other
extracellular matrix molecules. Impairments in this well-
organized pathway occur during atrial remodeling and fibrosis
(8). As a member of the MMP family, MMP-9 is known to be a
marker of enhanced proinflammatory and profibrotic pathway
activities. The study byWu et al. (1) included only patients with
persistent AF without apparent structural heart disease and
demonstrated an association between MMP-9 levels and AF
recurrence after catheter ablation for persistent AF; however,
their study lacked direct evidence regarding the mechanisms
underlying AF recurrence. The authors should have commen-
ted on their procedural electroanatomical mapping data, which
may have highlighted the mechanism underlying AF recur-
rence, in the event that the MMP-9 levels correlated with the
area of LA scar tissue (indicating LA fibrosis). Furthermore,
their study lacked data on whether the type of persistent AF
was primary or secondary in these patients. It was recently
proposed that persistent AF can occur either as a sustained
arrhythmia progressing from paroxysmal AF or as primary
persistent AF without any history of spontaneously terminating
episodes (9). Researchers have reported that the AF recurrence
rate after catheter ablation was significantly higher in patients
with primary persistent AF than in patients with secondary AF
progressing from paroxysmal AF. The authors also com-
mented on revolutionary studies demonstrating the failure
of using additional lines during catheter ablation to treat
persistent AF (10).
In conclusion, serum MMP-9 levels may significantly predict
the success rate of catheter ablation therapy in patients
with persistent AF, probably by indicating the extent of
LA fibrosis. However, additional non-invasive or invasive
measures should be used in conjunction with this biomarker
to predict the success rate of catheter ablation for the treat-
ment of persistent AF.
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